Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Syngene International Limited

Jonathan L Ditta

John E Macor

Joanne J Bronson

Carolyn Diane Dzierba

Ramkumar Rajamani

Derek John Denhart

Guanglin Luo

Susheel Jethanand Nara

Ling Chen

Tarun Kumar Maishal

Ronald J Mattson

Gene Michael Dubowchik

Ramesh Kumar Sistla

Dalton King

Lawrence R Marcin

Prasada Rao Jalagam

Soodamani Thangavel

Stephen R Bertenshaw

George O Tora

Kevin W Gillman

Andrew P Degnan

Ying Han

Vivekananda M Vrudhula

John D Catt

Mendi A Higgins

Zhaoxing Meng

Maheswaran Sivasamban Karatholuvhu

James R Epperson

Senliang Pan

David Paul Provencal

Jeffrey A Deskus

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia. 

Biaryl kinase inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Aryl lactam kinase inhibitors

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both. 

NK-1 and serotonin transporter inhibitors

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

Compounds for the treatment of premature ejaculation

The invention encompasses a series of tetrahydroisoquinolines of formula I which are antagonists of the human melatonin MTreceptor and are useful as chronobiotic and sleep agents.

Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists

Cyclopropylindole derivatives as selective serotonin reuptake inhibitors

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel pyrrolidinemethyl diamide and carbamate compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

Neurotrophic diamide and carbamate agents

Growing community of inventors

Meriden, CT, United States of America

Jonathan L Ditta